Literature DB >> 29880713

Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change.

Demetrios G Vavvas1, Kent W Small2, Carl Awh3, Brent W Zanke4, Robert J Tibshirani5,6, Rafal Kustra7.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29880713      PMCID： PMC6016766          DOI： 10.1073/pnas.1804781115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  8 in total

1.  Pharmacogenomics of antioxidant supplementation to prevent age-related macular degeneration.

Authors:  Andrew J Vickers
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-07       Impact factor: 11.205

2.  Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis.

Authors:  Johanna M Seddon; Rachel E Silver; Bernard Rosner
Journal:  Br J Ophthalmol       Date:  2016-07-28       Impact factor: 4.638

3.  Re: Assel et al.: Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration (Ophthalmology. 2018;125:391-397).

Authors:  Brent Zanke
Journal:  Ophthalmology       Date:  2018-05       Impact factor: 12.079

4.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

5.  Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study.

Authors:  Melissa J Assel; Fan Li; Ying Wang; Andrew S Allen; Keith A Baggerly; Andrew J Vickers
Journal:  Ophthalmology       Date:  2017-10-09       Impact factor: 12.079

6.  Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study.

Authors:  Carl C Awh; Steven Hawken; Brent W Zanke
Journal:  Ophthalmology       Date:  2014-09-04       Impact factor: 12.079

7.  No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38.

Authors:  Emily Y Chew; Michael L Klein; Traci E Clemons; Elvira Agrón; Rinki Ratnapriya; Albert O Edwards; Lars G Fritsche; Anand Swaroop; Gonçalo R Abecasis
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

8.  CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.

Authors:  Demetrios G Vavvas; Kent W Small; Carl C Awh; Brent W Zanke; Robert J Tibshirani; Rafal Kustra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205
  8 in total
  1 in total

1.  Novel Epigenetic Clock Biomarkers of Age-Related Macular Degeneration.

Authors:  Saurav Mallik; Fran Grodstein; David A Bennett; Demetrios G Vavvas; Bernardo Lemos
Journal:  Front Med (Lausanne)       Date:  2022-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.